MHI is a feasible fluorescence tracer for SLNB, with its dual advantages of visual clarity (like MB) and lymphatic specificity (like ICG). These combined advantages may enhance the accuracy and practicality of SLNB in breast cancer.
Li et al. (Wed,) studied this question.